Neurocrine Biosciences (NBIX) Income from Continuing Operations (2010 - 2026)

Neurocrine Biosciences has reported Income from Continuing Operations for 17 years, with the latest figure at 197900000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 2405.06% year-over-year to 197900000.0; the trailing twelve-month figure through Mar 2026 stood at 668600000.0 (up 118.64% YoY), and the FY2025 full-year result was 478600000.0, up 40.23% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 197900000.0, up from 153700000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 209500000.0 in Q3 2025, with the low at 76600000.0 in Q1 2023.
• Historically, Income from Continuing Operations has averaged 83647058.82 across 5 years, with a median of 89000000.0 in 2022.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations tumbled 651.08% — and 2026, when it soared 2405.06%.
• Neurocrine Biosciences' Income from Continuing Operations stood at 89000000.0 in 2022, then jumped by 65.96% to 147700000.0 in 2023, then slumped by 30.2% to 103100000.0 in 2024, then surged by 49.08% to 153700000.0 in 2025, then rose by 28.76% to 197900000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 197900000.0 (Q1 2026), 153700000.0 (Q4 2025), and 209500000.0 (Q3 2025), per Business Quant data.